FDA approved abiraterone acetate tablets plus prednisone for metastatic high-risk CSPC

/0 Comments/in , /by

 

  • FDA approved abiraterone acetate (Zytiga, Janssen Biotech Inc.) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). More Information.
You might also like
Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma
Trastuzumab-biosimilar Ontruzant® FDA approved in several indications
Single-agent pembrolizumab FDA approved for the first-line treatment of stage III NSCLC with PD-L1 TPS ≥1%
Discontinuation, post-discontinuation monitoring criteria, and guidance for treatment re-initiation in patients taking nilotinib for Ph+ CML with a sustained molecular response
Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC
FDA approved a broadened indication of afatinib in the 1st-line treatment of metastatic NSCLC with non-resistant EGFR mutations
Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)
Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

FDA approved lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive...FDA approves apalutamide for non-metastatic castration-resistant prostate c...